Dr. Nastoupil is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161Fax+1 713-794-5656
Education & Training
- Emory University School of MedicineFellowship, Hematology and Medical Oncology, 2010 - 2013
- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2007 - 2010
- University of Texas Southwestern Medical SchoolClass of 2007
Certifications & Licensure
- FL State Medical License 2021 - Present
- AZ State Medical License 2022 - 2026
- CO State Medical License 2024 - 2025
- TN State Medical License 2022 - 2025
- TX State Medical License 2013 - 2025
- WA State Medical License 2022 - 2025
- AL State Medical License 2022 - 2024
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Clinical Trials
- Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects Start of enrollment: 2016 May 01
- A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. Start of enrollment: 2020 Jun 11
- A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) Start of enrollment: 2021 Nov 12
Roles: Principal Investigator
- Join now to see all
Publications & Presentations
PubMed
- Phase 2 trial of ibrutinib and nivolumab in patients with relapsed CNS lymphomas.Dai Chihara, Raphael E Steiner, Ranjit Nair, Lei Feng, Sairah Ahmed
Blood Advances. 2025-04-08 - Outcomes of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With R-GemOx: A Multicenter Cohort Study.Samuel Yamshon, Jean L Koff, Melissa C Larson, Brad S Kahl, Carla Casulo
American Journal of Hematology. 2025-04-01 - Real-World Effectiveness of Chemoimmunotherapy and Novel Therapies for Patients With Relapsed/Refractory Aggressive Large B-Cell Lymphoma.Loretta J Nastoupil, Clark R Andersen, Amy Ayers, Yucai Wang, Thomas M Habermann
Clinical Lymphoma, Myeloma & Leukemia. 2025-04-01
Journal Articles
- Assessment of Radiation Doses Delivered to Organs at Risk Among Patients with Early-Stage Favorable Hodgkin Lymphoma Treated with Contemporary Radiation TherapyChelsea C Pinnix, Jillian R Gunther, Sarah A Milgrom, Jason Westin, Simrit Parmar, Loretta Nastoupil, Sattva Neelapu, Bouthaina S Dabaja, JAMA Network Open
- Characteristics of Patients with Myeloproliferative Neoplasms with Lymphoma, with or Without JAK Inhibitor TherapyNaveen Pemmaraju, Hagop Kantarjian, Loretta Nastoupil, Srdan Verstovsek, Blood
- Venetoclax, Bendamustine, and Rituximab in Patients with Relapsed or Refractory NHL: A Phase 1b Dose-Finding StudyN Fowler, E Reid, L J Nastoupil, Annals of Oncology
Abstracts/Posters
- A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or...Loretta J. Nastoupil, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Comparative Review of 30 Day Non-Relapse Mortality (NRM) in B-Cell Lymphomas Associated with Anti-CD19 Chimeric Antigen Receptor T-Cells (CAR-T) from FDA Database, Cli...Loretta J. Nastoupil, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/9/2019
- Comparative Outcomes of Relapsed Follicular Lymphoma Patients Treated with Novel Agents: A Multi-Center AnalysisLoretta J. Nastoupil, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Addressing Current Questions and Controversies in the Management of Lymphomas and Chronic Lymphocytic Leukemia (Part 1 of a 2-Part Series)61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Results of a First in Human, Dose Ascending, Phase I Study Examining the Safety and Tolerability of KA2237, an Oral PI3K p110_/_ Inhibitor in Patients with Relapsed/Re...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Follicular Lymphoma: Have We Made Progress?60th American Society of Hematology Annual Meeting - 12/3/2018
- Join now to see all
Press Mentions
- 6 Things We’ve Learned About CAR T Cell TherapyNovember 1st, 2022
- CAR T Cell Therapy Put Me into Complete Remission After a Non-Hodgkin Lymphoma DiagnosisSeptember 26th, 2022
- CAR T Cell Therapy Put Me into Complete Remission After a Non-Hodgkin Lymphoma DiagnosisSeptember 26th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: